PreClara Ratio (sFlt-1/PlGF)

Bringing clarity to preeclampsia risk assessment

The PreClara Ratio (sFlt-1/PlGF) is the first FDA-cleared biomarker test for the risk assessment of preeclampsia with severe features

The PreClara™ Ratio (sFlt-1/PlGF) offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing.[1] The ratio should be used in conjunction with other laboratory tests and standard clinical assessment.

The test, derived from patient serum or plasma and run on the KRYPTOR™ immunoassay analyzer, measures two placental biomarkers: soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) – which are linked to the development of preeclampsia.[2]

Key clinical benefits[3,4]

May improve clinical decision making regarding:

- Stepped-up care and surveillance
- Transfer to tertiary care center
- Resource allocation and cost optimization
- Patient and family counseling

Clinically validated–PRAECIS study[2]

Prospective U.S. multi-center study across 18 tertiary and community hospitals, including 1,014 pregnant women hospitalized for hypertensive disorders of pregnancy.

Click here or scan QR code to view publication

Clinically proven–BEACON study[3]

Real-world evidence for implementation and utilization of sFlt-1/PlGF for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy.

Click here or scan QR code to view publication

Intended use

The PreClara Ratio (sFlt-1/PlGF) is to be used in conjunction with other laboratory tests and clinical assessments to aid in the risk assessment of pregnant women (singleton pregnancies between 23+0 and 34+6/7 weeks gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features* within two weeks of presentation. The PreClara Ratio must be calculated using the B·R·A·H·M·S sFlt-1 KRYPTOR and the B·R·A·H·M·S PlGF plus KRYPTOR results measured on the B·R·A·H·M·S KRYPTOR analyzer.

* As defined by American College of Obstetricians and Gynecologists guidelines

B·R·A·H·M·S KRYPTOR compact PLUS

Fully-automated, random-access, **benchtop** immunoassay analyzer delivering **highly robust** and **precise results**

Key instrument features

- Fast time to results (under 30 minutes)
- Optimized workflow with intelligent features
- Biotin free, separation free, and wash free with TRACE™ technology

Automated assays available on KRYPTOR

PCT for
bacterial infections

sFlt-1/PlGF
for preeclampsia

CgA for
GEP-NETs

References

1. US IFU PreClara Ratio (sFlt-1/PlGF)
2. Thadhani, et al. Circulating angiogenic factor levels in hypertensive disorders of pregnancy. NEJM Evid 2022;1:EVIDoa2200161.
3. Khosla, et al. Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States, Pregn Hyperten 2021; 26:121-126.
4. Burns LP, Potchileev S...Rana S. Real-World Evidence for Utility of Serum sFlt-1/PlGF Test for Routine Clinical Evaluation of Hospitalized Women with Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 2024 Jul 17:S0002-9378(24)00758-0. PMID: 39029547.

Learn more at **thermofisher.com/preeclampsia** or email us at **info.preclara@thermofisher.com**

PreClara Ratio (sFlt-1/PlGF) is also referenced as the B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System in public documents, publications, and other materials.